SCHEMBL39947

SCHEMBL39947

CNC(CCCCNC(=O)c1[nH]c2ccccc2c1-c1ccoc1)c1ccccn1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
MAP3K5 Q99683 1/20 0.42
GAA P10253 1/20 0.37
HDAC3 O15379 7/20 0.36
HDAC1 Q13547 7/20 0.36
MCL1 Q07820 2/20 0.34
TDO2 P48775 1/20 0.34
HDAC4 P56524 6/20 0.34
HDAC7 Q8WUI4 6/20 0.34
HDAC2 Q92769 6/20 0.34
HDAC10 Q969S8 6/20 0.34
HDAC11 Q96DB2 6/20 0.34
HDAC8 Q9BY41 6/20 0.34
HDAC6 Q9UBN7 6/20 0.34
HDAC9 Q9UKV0 6/20 0.34
HDAC5 Q9UQL6 6/20 0.34
HTR1A P08908 2/20 0.34
DRD2 P14416 2/20 0.34
HTR2A P28223 2/20 0.34
CAPN1 P07384 1/20 0.33
MEN1 O00255 1/20 0.33

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL13151483 0.67 ALDH1A1 (0.46) GAAPOLB
SCHEMBL9212419 0.67 GAA (0.62) GAAHDAC3HDAC1RAB9AUSP2
SCHEMBL40526 0.66 KDM4E (0.69) MAP3K5GAATDO2MEN1POLB
SCHEMBL39931 0.66 MAPT (0.48) GAAMEN1POLBKMT2A
SCHEMBL39913 0.65 ALDH1A1 (0.55) GAAHTR1ADRD2
SCHEMBL39923 0.64 OPRK1 (0.45) GAAPOLBKMT2A
SCHEMBL24073014 0.64 GAA (0.60) GAAHDAC3HDAC1MCL1MEN1
SCHEMBL28622173 0.63 ALDH1A1 (0.46) GAAMEN1RAB9AKMT2A
SCHEMBL40517 0.62 HRH1 (0.42)
SCHEMBL3717619 0.61 LMNA (0.40) GAAMEN1RAB9AKMT2A

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 9 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2419408-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K. (JP) 2012-02-22 EP claimed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US claimed
WO-2010119984-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-10-21 WO claimed
EP-2419408-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K. (JP) 2012-02-22 EP disclosed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE MSD K.K 2012-02-02 US disclosed
WO-2010119984-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-10-21 WO disclosed
WO-2010119984-A1 3-ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE BANYU PHARMACEUTICAL CO.,LTD. (JP) 2010-10-21 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20120028990-A1 3 ARYL OR HETEROARYL-SUBSTITUTED INDOLE DERIVATIVE IDO1, TPH1, AHR MAP3K5 3403/4885GAA 2702/4885HDAC3 159/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.